ReviewFrontiers in oncology2025
Significance of ARID1A in neuroblastoma onset mechanism.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma (NB) is a prevalent pediatric malignancy with poor clinical outcomes. As one of the most common childhood malignancies, it can arise in various locations along the sympathetic nervous system, complicating both fundamental studies and therapeutic approaches. The ARID1A protein has emerged as a pivotal regulator in the pathogenesis of diverse tumor types within oncology research. Recent studies have increasingly focused on the functional role of ARID1A in NB pathogenesis. As a tumor suppressor, ARID1A loss-of-function mutations enhance migratory and invasive capacities of NB cells through cell cycle dysregulation, thereby promoting tumor cell proliferation. At the molecular level, ARID1A functions as the core subunit of the BAF chromatin remodeling complex, critically regulating the proliferative behavior of tumor cells. Although research in this field remains at an early stage, it has established a solid foundation for elucidating NB pathogenesis, with promising implications for improving clinical outcomes and quality of life in affected children. This review summarizes the critical role of ARID1A in NB and explores emerging therapeutic strategies, with particular emphasis on targeted protein degradation approaches and immunotherapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.